Pharma BD Deal Intelligence
Agilent Technologies acquired Resolution Bioscience for $550 million in cash at closing plus up to $145 million in performance milestones (total up to $695 million), expanding Agilent's capabilities in NGS-based liquid biopsy cancer diagnostics and precision medicine. Post-close, the acquired platform delivered Agilent's first FDA-approved liquid-biopsy companion diagnostic: the Agilent Resolution ctDx FIRST (PMA P210040) won FDA approval on December 12, 2022 as the first liquid-biopsy CDx to identify KRAS G12C-mutated advanced NSCLC patients eligible for Krazati (adagrasib, Mirati Therapeutics), and in January 2023 Agilent partnered with Quest Diagnostics to extend US national access to the test.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Agilent Technologies Inc. / Resolution Bioscience Inc. (this deal) | 2021 | $695M | 32 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2021 deals · Oncology deals